Cyclopharm’s lung imaging technology is breathing new life into the company’s bottom line, with its Technegas product surpassing the million-dollar milestone in US sales, according to Tuesday’s ASX announcement. The Sydney-based company has rapidly expanded its American footprint, with Technegas systems now installed in 27 US medical facilities as of 31 March 2025 – a…
Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress of lung transplantation. The use is detailed in a US-based study which highlights the clinical utility and operational benefits of the Technegas technology compared to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.…
The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…
The federal government is to fund construction of a new nuclear medicine manufacturing facility at the Australian Nuclear Science and Technology Organisation’s (ANSTO) Lucas Heights complex in Sydney. The government did not estimate the cost of the facility, reportedly likely to be in the hundreds of millions of dollars, which will replace the ageing Building…
